Thyroid sequelae of COVID-19: a systematic review of reviews

Pierpaolo Trimboli1,2 · Chiara Camponovo1 · Lorenzo Scappaticcio3 · Giuseppe Bellastella3 · Arnoldo Piccardo4 · Mario Rotondi5,6

Accepted: 5 April 2021 / Published online: 11 April 2021 © The Author(s) 2021

Abstract

The coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has the potential to cause multi-organ effects including endocrine disorders. The impact of COVID-19 on the thyroid gland has been described but several aspects have to be clarified. The systematic review was conceived to achieve more solid information about: 1) which thyroid disease or dysfunction should be expected in COVID-19 patients; 2) whether thyroid patients have a higher risk of SARS-CoV-2 infection; 3) whether the management has to be adapted in thyroid patient when infected. The literature was searched by two authors independently. A 5-step search strategy was a priori adopted. Only reviews focused on the relationship between thyroid and COVID-19 were included. The last search was performed on February 21st 2021. Two-hundred-forty-seven records was initially found and nine reviews were finally included. The reviews identified several potential thyroid consequences in COVID-19 patients, such as thyrotoxicosis, low-T3 syndrome and subacute thyroiditis, while no relevant data were found regarding the potential impact of COVID-19 on the management of patients on thyroid treatment. The present systematic review of reviews found that: 1) patients diagnosed with COVID-19 can develop thyroid dysfunction, frequently non-thyroidal illness syndrome when hospitalized in intensive care unit, 2) having a thyroid disease does not increase the risk for SARS-CoV-2 infection, 3) thyroid patients do not need a COVID-19-adapted follow-up. Anyway, several factors, such as critical illness and medications, could affect thyroid laboratory tests.

Keywords Thyroid · COVID-19 · Coronavirus · Thyroiditis

1 Introduction

In March 2020, WHO declared the pandemic of the novel coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) [1]. Since then, about 111 million cases and 2.5 million deaths from SARS-CoV-2 were reported until February 2021 [2]. What has been shocking for the whole medical scientific community is that SARS-CoV-2 has a wide spectrum of clinical severity, ranging from a- or pauci-symptomatic presentation to disease-specific mortality [3]. COVID-19 has the potential to cause upper respiratory tract, pulmonary and systemic inflammation, determining multi-organ dysfunction especially in frail patients [4]. These latter are also at higher risk of COVID-19 specific death. Among the various clinical effects of SARS-CoV-2, the endocrine ones have been investigated. Importantly, diabetic patients were proven to be at higher risk for infection and poorer prognosis when infected [5]. Moreover, treatment modifications are required as a consequence of COVID-19 in patients affected by endocrine
diseases, such as diabetes, adrenal insufficiency, hypo- or hyper-naatraemia [5, 6]. In addition, the impact of COVID-19 on thyroid gland has been described by direct or indirect effect [7].

In the thyroid field many original papers, several case reports, and some recommendations by endocrine societies on the impact of COVID-19 have been published. Furthermore, a not negligible number of narrative and systematic review articles on this topic have been conducted. Overall, although several clues would suggest a possible relationship between thyroid gland and SARS-CoV-2, and even if the presence of the receptor for SARS-CoV-2 entry (i.e., angiotensin-converting enzyme 2 [ACE-2]) in thyroid cells has been proven [8, 9], which thyroid consequences can be observed in patients diagnosed with COVID-19 remains to be fully clarified.

The present study was conceived to provide more solid information about three specific items: 1) which thyroid disease or dysfunction can be expected in COVID-19 patients; 2) whether thyroid patients have a higher risk of SARS-CoV-2 infection; 3) whether the management has to be adapted in thyroid patient when infected by SARS-CoV-2. Therefore, it was designed a systematic review of reviews published on this topic, the conclusions of the retrieved articles were summarized, and the summary of findings discussed.

2 Materials and methods

2.1 Review conduction

The systematic review was conducted according to the methodology proposed by Aromataris et al. [10].

2.2 Search strategy

The literature was searched by two authors independently (PT and LS). A 5-step search strategy was a priori adopted: 1) sentinel studies were sought in PubMed using multiple combinations of the following keywords: thyroid, SARS-CoV-2, coronavirus, COVID, COVID-19; 2) keywords and MeSH terms were identified in PubMed; 3) PubMed, CENTRAL, Scopus, and Web of Science were searched; 4) narrative reviews, systematic reviews and meta-analyses with potential to be eligible were identified; 5) reviews focused only on the relationship between thyroid and COVID-19 were directly included in the study while those focusing on the general endocrine impact by COVID-19 were screened and included only when having a large section dedicated to thyroid. The last search was performed on February 21st 2021. To find additional studies and expand the search, the references of the articles retrieved were also screened.

2.3 Data extraction

For each included article the following information was extracted by two authors independently (CC and LS): authors, country, date of the last literature search, date of publication, journal, type of review (i.e., narrative review, systematic review, systematic review with meta-analysis), context of the review (i.e., thyroid field or endocrinology), aim of the review, conclusions of the authors. Also, the type of thyroid sequelae (i.e., diseases or dysfunction) were extracted.

3 Results

3.1 Reviews retrieved

By the search strategy, a number of 247 records was initially found. Among these, according to the above criteria, 238 studies were excluded since they were not review articles, and nine reviews were finally included [7, 11–18] (Fig. 1).

The nine included reviews were conducted by European, American and Asian authors. The date of the last literature search was reported in three studies and varied from September to December 2020. Seven studies were narrative review and two were systematic review. Both objectives and conclusions of the nine reviews were clearly reported. However, since the largest part of the retrieved reviews was narrative, their pre-defined patient-centered questions (e.g., PICOS, participants, interventions, comparators, outcomes, and study design) were not reported. Table 1 summarizes the main features of the reviews included in the present systematic review.

Fig. 1 Search strategy and flow of articles
3.2 Findings of the reviews included

The aim and the main conclusions of the nine reviews were schematically reported in the Table 2. Briefly, the reviews identified several potential thyroid consequences in COVID-19 patients, while no relevant data were found regarding the potential impact of COVID-19 on the clinical/therapeutic management of patients with thyroid diseases. Patients with SARS-CoV-2 infection can develop thyrotoxicosis or low-T3 syndrome and should be at risk to develop subacute thyroiditis (SAT). Regarding the rate of these complications/dysfunctions, no significant data were found in the reviews included in the present systematic review. Furthermore, having a thyroid disease should not be considered a risk factor for SARS-CoV-2 infection. The summary of findings of the present systematic review was reported in Table 3 to facilitate the presentation of the results.

4 Discussion

With the beginning of COVID-19 pandemic, we faced a tsunami of publications. This is true also for the endocrine and thyroid field. However, after one year since the WHO declaration of pandemic, we should need taking stoke of the situation. We have several clues that SARS-CoV-2 can have effects on the thyroid gland. High levels of expression of ACE2 receptor and transmembrane protease serine 2 have been found in thyroid cells [8, 9], abnormal immune responses and cytokine storm associated to COVID-19 may induce thyroid gland inflammation [9, 19], and both direct and indirect mechanisms might affect hypotalamic-pituitary-thyroid axis [20–24].

Based on the above evidences, and according to the sparse knowledge on this topic, a systematic review was designed and a number of nine reviews focused on the relationship between thyroid and SARS-CoV-2 were retrieved. Unfortunately, among the reviews included seven, were narrative reviews that do not represent an evidence-based information as the systematic ones well. Regarding the first question of the present review, the pooled findings from the included reviews allow us to conclude as follows. A subject diagnosed with COVID-19 can: 1) develop thyroid dysfunction due to direct and indirect damage on the thyroid gland; 2) have a low-T3 syndrome if hospitalized due to severe COVID-19 infection; 3) eventually develop SAT. In the nine reviews we did not find clear data allowing to establish the real prevalence of these scenarios. Concerning the other two questions we raised with this review, we can conclude that having a thyroid disease does not represent a risk for infection of SARS-CoV-2 and does not require specific recommendations.

The COVID-19 pandemic has dramatically influenced our daily life and has abruptly shifted the medical research. Furthermore, we have faced a huge medical information, also in the thyroid field, that was often conflicting with each other [25]. Following these considerations, the results from the present paper should be discussed with caution and with the aim to provide further insights from a clinical point of view. It is recognized that patients with severe systemic disease generally show altered thyroid laboratory tests [26]. Also,
Table 2  Aim and main conclusions of the reviews included in the present systematic review

| First author [ref] | Aim | Main conclusions |
|--------------------|-----|-----------------|
| Dworakowska [11]   | To explore COVID-19 risks in patients with preexisting thyroid problems. To review current literature on thyroid diseases (excluding cancer) and COVID-19, including data from the previous coronavirus pandemic caused by the SARS-CoV | There are no data suggesting that thyroid patients are at higher risk of COVID-19. In patients severely affected by COVID-19, changes in thyroid function may relate to a ‘sick euthyroid’ syndrome, but there may be specific thyroid-related damage which requires further investigation |
| Gorini [12]        | To summarize the main findings on thyroid and COVID-19 and define research lines aimed at patient care and effective public health measures | Thyroid disease is not a risk factor for the development of COVID-19, and a higher prevalence of thyroid disease has not been found in patients with COVID-19. Questioning patients about the presence of thyroid disease at the time of hospitalization with subsequent follow-up might be useful in patients with multiple diseases to avoid thyrotoxicosis first and hypothyroidism later resulting from SAT |
| Caron [13]        | To discuss the diagnosis and the management of patients presenting with thyrotoxicosis, thyroid-associated orbitopathy and hypothyroidism in the context of SARS-CoV-2 infection | Routine assessment of thyroid function in the acute phase for COVID-19 patients requiring intensive care is useful, as they frequently present thyrotoxicosis related to SARS-CoV-2, and during convalescence to diagnose and adapt levothyroxine replacement treatment in patients with primary or central hypothyroidism |
| Scappaticcio [7]   | To explore the impact of COVID-19 on the thyroid gland | SAT mainly occurs during or soon after mild COVID-19. Thyrotoxicosis without neck pain (possibly in the context of the nonthyroidal illness syndrome) could characterize more severe and critical cases of COVID-19 pneumonia. Some clues of the hormonal changes (i.e., low T3 and TSH concentrations) and overt thyrotoxicosis to be regarded as predictors of poor outcome of COVID-19 are already emerging |
| Kumari [14]        | To explore the potential role of prevailing thyroid disorders in SARS-CoV-2 infection | Thyroid dysfunction may have considerable risk in aggravating the infection and spread of SARS-CoV-2, and it is closely associated with aging |
| Chen [15]          | To review the potential interaction between COVID-19 and the thyroid gland, including thyroid pathology, function and diseases. To explore the potential harmful effects of COVID-19 drugs on the thyroid | SAT caused by SARS-CoV-2 has been reported. The alteration of thyroid tests is common among COVID-19 patients. However, there is no pathological evidence of thyroid injury caused by SARS-CoV-2. Some anti–COVID-19 agents may cause thyroid injury or affect its function |
| Speer [16]         | To explore and compare the impact of SARS-CoV and SARS-CoV-2 on the thyroid gland | No increase of prevalence of pre-existing thyroid disorder in SARS-CoV and SARS-CoV-2 patients was found. However, routine screening of thyroid function at least in COVID-19 patients requiring hospitalization is suggested, because subacute thyroiditis might be a late complication |
| Croce [17]         | To summarize studies regarding thyroid function alterations in patients with COVID-19 | Non-thyroid illness syndrome is the most consistently observed alteration of thyroid function parameters. SARS-CoV-2 may also infect the thyroid producing typical (painful) or atypical (painless) subacute thyroiditis |
| Piticchio [18]     | To discuss the relationship between COVID-19 infection and the endocrine glands and compare it with SARS-CoV | A possible damage of endocrine system in COVID-19 patients should be investigated in both COVID-19 acute phase and recovery to identify both early and late endocrine complications that may be important for patient’s prognosis and well-being after infection |

COVID-19 coronavirus disease 2019, SARS-CoV-2 severe acute respiratory syndrome coronavirus 2, SAT subacute thyroiditis
it is known that patients in the intensive care unit typically present with decreased tri-iodothyronine, low thyroxine, and normal range or slightly decreased TSH (i.e., non-thyroidal illness syndrome or low-T3 syndrome), even if no proof exists for causality of this association [27]. Furthermore, it is known that thyroid hormones levels can hold a role to predict a worse prognosis in these patients [27]. The larger part of studies investigating thyroid function in COVID-19 patients enrolled critically ill subjects. Then, it should be not surprising that also COVID-19 patients present with this thyroid hormone profile, which should not be specifically ascribed to COVID-19. A certain role for systemic inflammation might also be envisaged. Indeed, the cytokine storm occurring during SARS-CoV-2 infection often results in an uncontrolled inflammatory response that is detrimental to host cells [17, 22]. As far as the thyroid gland is concerned, it should be highlighted that several models, including the chronic low-level inflammation associated with aging, the so-called “inflammaging” [28], and the oxidant/antioxidant imbalance associated with thyroid chronic inflammation [29], proved to have a role in the pathogenesis of thyroid diseases. From this point of view, there is potential to consider a thyroid role in the long-term effects of COVID-19.

In addition, it has to be taken into account that the evaluation of thyroid function in COVID-19 patients can be influenced by a number of the medications received [30]. Heparin has been largely used in COVID-19 patients and it is known to interfere in free thyroid hormones assays. In fact, heparin liberates lipoprotein lipase from the vascular endothelium, and blood samples from heparin-treated patients have increased lipoprotein lipase activity generating non-esterified fatty acids (NEFA). Free thyroid hormone assays, especially those with prolonged incubation periods, are affected since NEFA displace T4 and T3 from binding proteins, causing spuriously high values [31]. Patients with severe COVID-19 can develop a systemic inflammatory response and corticosteroids have been largely used because of their powerful anti-inflammatory effects. However, corticosteroids can influence thyroid laboratory tests by several pathways: act on hypothalamic-pituitary control on the thyroid reducing TSH, reduce levels of thyroxine-binding globulin and increase free T4, and inhibit thyroid hormone activation (i.e., conversion from T4 to T3). Finally, it cannot be excluded that COVID-19 patients have been exposed to multiple chest iodinated contrast-enhanced computed tomography which can obviously determines a transient thyrotoxicosis.

Some considerations on the possible occurrence of SAT in patients experiencing COVID-19 should be drawn. Indeed, these descriptions mainly rely on case reports [7]. As a consequence, there is no definite proof about this possible COVID-19 complication, and the true frequency of SAT among COVID-19 is unknown. SAT might occur a few weeks after a viral infection of the upper respiratory tract, and then it might be a late complication of COVID-19. Here we systematically reviewed all reviews published on the relationship between thyroid and COVID-19. The nine reviews we included in our study were published between June 2020 and February 2021 and more recent original studies were not included. Then, some conclusions we achieved might be changed. Regarding the possible need to adapt the management of thyroid patients when infected by SARS-CoV-2, even if we did not find strong information, it has to be cited the recent bulletin by European Thyroid Association [32] quoting that no consequences have to be expected in patients receiving treatment for hypothyroidism or hyperthyroidism [33, 34].

The present systematic review has some limitations to be disclosed. First, published data on the relationship between thyroid and SARS-CoV-2 are limited and sparse. Second, we found almost only narrative reviews that do not represent
an evidence-based information. Third, the COVID-19 pandemic is still going on and data we found in the reviews should be revised in the next studies.

In conclusion, the present systematic review of reviews found that: 1) patients diagnosed with COVID-19 can develop thyroid dysfunction, frequently non-thyroidal illness syndrome when hospitalized in intensive care unit, 2) having a thyroid disease does not increase the risk for SARS-CoV-2 infection, 3) thyroid patients do not need a COVID-19-adapted follow-up. Anyway, it has to be taken into account that several COVID-19 intrinsic factors, such as critical illness and medications, could affect thyroid laboratory tests. Since the rapid worldwide diffusion of SARS-CoV-2 and its variants, it is highly important to annotate that the summary of findings of the present study might change in the next future.

Abbreviations  ACE-2: Angiotensin-converting enzyme 2; COVID-19: Coronavirus disease 2019; NEFA: Non-esterified fatty acids; SARS-CoV-2: Severe acute respiratory syndrome coronavirus 2; SAT: Subacute thyroiditis

Author contributions  PT conceived and designed the review article; PT and LS performed the literature search; CC and LS extracted findings; PT, AP, GB and MR analyzed and interpreted the data; all authors revised the manuscript and approved the final version.

Funding  Open Access funding provided by Università della Svizzera italiana.

Declarations

Conflict of interest  The authors declare that they have no conflict of interest.

Open Access  This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, and indicate if changes were made.

References

1. WHO Director-General’s opening remarks at the media briefing on COVID-19. News release. March 11, 2020. Accessed 12 Mar 2020. https://www.who.int/dg/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020

2. https://gisanddata.maps.arcgis.com/apps/opsdashboard/index.html#/bda7594740d40299423467b48e9c0f6 (last update February 21th, 2021)

3. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395:497–506. https://doi.org/10.1016/S0140-6736(20)30183-5

4. Chen T, Wu D, Chen H, et al. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study. BMJ. 2020;368:m1091. https://doi.org/10.1136/bmj.m1091

5. Marazuela M, Giustina A, Puig-Domingo M. Endocrine and metabolic aspects of the COVID-19 pandemic. Rev Endocr Metab Disord. 2020;1–13. https://doi.org/10.1007/s11154-020-09569-2

6. Fernandez Martinez A, Barajas Galindo D, Ruiz SJ. Management of hyponatraemia and hypernatraemia during the Covid-19 pandemic: a consensus statement of the Spanish Society for Endocrinology (Acqua Neuroendocrinology Group). Rev Endocr Metab Disord. 2021;5:1–8. https://doi.org/10.1007/s11154-021-09627-3

7. Scappaticcio L, Pitoia F, Esposito K, Piccardo A, Trimболl P. Impact of COVID-19 on the thyroid gland: an update. Rev Endoc Metab Disord. 2020;25:1–13. https://doi.org/10.1007/s11154-020-09615-z

8. Rotondi M, Coperchini F, Ricci G, Denegri M, Croce L, Ngnieteju ST, Villani L, Magri F, Latrofa F, Chiovato L. Detection of SARS-CoV-2 receptor ACE-2 mRNA in thyroid cells: a clue for COVID-19-related subacute thyroiditis. J Endocrinol Invest. 2020;6(1):6. https://doi.org/10.1007/s40618-020-01436-w

9. Li MY, Li L, Zhang Y, Wang XS. Expression of the SARS-CoV-2 cell receptor gene ACE2 in a wide variety of human tissues. Infect Dis Poverty. 2020;9(1):45. https://doi.org/10.1186/s40249-020-00662-x

10. Aromataris E, Fernandez R, Godfrey CM, Holly C, Khalil H, Tungpunpoom P. Summarizing systematic reviews: methodological development, conduct and reporting of an umbrella review approach. Int J Evid Based Healthc. 2015;13(3):132–40. https://doi.org/10.1097/XEB.0000000000000055

11. Dworakowska D, Grossman AB. Thyroid disease in the time of COVID-19. Endocrine. 2020;68(3):471–4. https://doi.org/10.1007/s40618-020-01436-w

12. Gorini F, Bianchi F, Iervasi G. COVID-19 and Thyroid: Progress and Prospects. Int J Environ Res Public Health. 2020;17(18):6630. https://doi.org/10.3390/ijerph17186630

13. Caron P. Thyroid disorders and SARS-CoV-2 infection: From pathophysiological mechanism to patient management. Ann Endocrinol (Paris). 2020;81(5):507–10. https://doi.org/10.1016/j.ando.2020.09.001

14. Kumari K, Chainy GBN, Subudhi U. Prospective role of thyroid disorders in monitoring COVID-19 pandemic. Heliyon. 2020;6(12):e05712. https://doi.org/10.1016/j.heliyon.2020.e05712

15. Chen W, Tian Y, Li Z, Zhu J, Wei T, Lei J. Potential interaction between SARS-CoV-2 and thyroid: A review. Endocrinology. 2021 Mar 1;162(3):bqab004. https://doi.org/10.1210/endo/bqab004

16. Speer G, Somogyi P. Thyroid complications of SARS and coronavirus disease 2019 (COVID-19). Endocr J. 2021;68(2):129–36. https://doi.org/10.1507/endocrj.EJ20-0443

17. Croce L, Gangemi D, Ancona G, Liboià F, Bendotti G, Minelli L, Chiovato L. The cytokine storm and thyroid hormone changes in COVID-19. J Endocrinol Invest. 2021;9:1–14. https://doi.org/10.1007/s40618-021-01506-7

18. Pitticchio T, Le Moli R, Tumino D, Frasca F. Relationship between betacoronaviruses and the endocrine system: a new key to understand the COVID-19 pandemic-A comprehensive
review. J Endocrinol Invest. 2021;13:1–18. https://doi.org/10.1007/s40618-020-01486-0
19. Kerslake R, Hall M, Randeva HS, et al. Co-expression of peripheral olfactory receptors with SARS-CoV-2 infection mediators: Potential implications beyond loss of smell as a COVID-19 symptom. Int J Mol Med. 2020;46(3):949–956. https://doi.org/10.3892/ijmm.2020.4646
20. Ackermann M, Verleden SE, Kuehnel M, et al. Pulmonary Vasculitis, Thrombosis, and Angiogenesis in Covid-19. N Engl J Med 2020;383(2):120–128. https://doi.org/10.1056/NEJMoa2015432
21. Dufort EM, Koumans EH, Chow EJ, et al. Multisystem Inflammatory Syndrome in Children in New York State. N Engl J Med 2020;383(4):347–358. https://doi.org/10.1056/NEJMoa2021756
22. Coperchini F, Chiovato L, Ricci G, Croce L, Magri F, Rotondi M. The cytokine storm in COVID-19: Further advances in our understanding the role of specific chemokines involved. Cytokine Growth Factor Rev. 2021;S1359–6101(20):30242–52. https://doi.org/10.1016/j.cytoogrfr.2020
23. Java A, Apicelli AJ, Liszewski MK, et al. The complement system in COVID-19: friend and foe?. JCI Insight. 2020;5(15):140711. https://doi.org/10.1172/jci.insight.140711
24. Guo Y, Korteweg C, McNutt MA, Gu J. Pathogenetic mechanisms of severe acute respiratory syndrome. Virus Res. 2008;133(1):4–12. https://doi.org/10.1016/j.virusres.2007.01.022
25. Rotondi M, Nieto-Diaz M, Magri F, Oliviero A. Balancing the need for rapid and rigorous scientific data during early phase of the COVID-19 pandemic: A further role for the scientific community. Eur J Intern Med. 2020;77:152. https://doi.org/10.1016/j.ejim.2020.05.037
26. Mebis L, Debaveye Y, Visser TJ, Van den Berghhe G. Changes within the thyroid axis during the course of critical illness. Endocrinol Metab Clin North Am. 2006;35(4):807–21.
27. Fliers E, Bianco AC, Langouche L, Boelen A. Thyroid function in critically ill patients. Lancet Diabetes Endocrinol. 2015;3(10):816–25.
28. Franceschi C, Ostani R, Mariotti S, Monti D, Vitale G. The Aging Thyroid: A Reappraisal Within the Geroscience Integrated Perspective. Endocr Rev. 2019;40(5):1250–70. https://doi.org/10.1210/er.2018-00170
29. Ruggeri RM, CampennÎ A, Giuffrida G, Casciaro M, Barbalace MC, Hrelia S, Trimarchi F, CannavÔ S, Gangueli S. Oxidative stress as a key feature of autoimmune thyroiditis: an update. Minerva Endocrinol. 2020;45(4):326–44. https://doi.org/10.23736/S0391-1977.20.03268-X
30. Cipappa PE, Cugnata F, Ferrari P, Brombin C, Ruinelli L, Bianchi G, Beria N, Schulz L, Bernasconi E, Merlani P, Ceschi A, Di Serio C. A data-driven approach to identify risk profiles and protective drugs in COVID-19. Proc Natl Acad Sci U S A. 2021;118(1):e2016877118. https://doi.org/10.1073/pnas.2016877118.Erratum In: Proc Natl Acad Sci USA. 2021Feb23;118(8):PMID:33303654;PMCID:PMC7817222
31. Mendel CM, Frost PH, Kunitake ST, Cavalieri RR. Mechanism of the heparin-induced increase in the concentration of free thyroxine in plasma. J Clin Endocrinol Metab. 1987;65(6):1259–64.
32. SARS-CoV-2 and Hypo-/Hyperthyroidism - eurothyroid.com. February 20th, 2021
33. van Gerwen M, Alsen M, Little C, Barlow J, Naymagon L, Tremblay D, Sinclair CF, Genden E. Outcomes of patients with hypothyroidism and COVID-19: A retrospective cohort study. Front Endocrinol (Lausanne). 2020;18(11):565. https://doi.org/10.3389/fendo.2020.00565
34. Brix TH, Hegedûs L, Hallas J, Lund LC. Risk and course of SARS-CoV-2 infection in patients treated for hypothyroidism and hyperthyroidism. Lancet Diabetes Endocrinol. 2021;S2213–8587(21):00028. https://doi.org/10.1016/S2213-8587(21)00028-0
Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.